Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Operating cash flow
Replimune Group, Inc.'s operating cash flow for fiscal 2026 was −$280.3M, compared with −$192.3M in fiscal 2025. Over the twelve months to 30 September 2026 it was −$245.5M. Over the past ten years it has ranged from −$280.3M (fiscal 2026) to −$7.1M (fiscal 2017) — the current reading is the lowest in ten years. Operating cash flow has fallen for 9 consecutive fiscal years. Replimune Group, Inc. ranks 559th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | −$280.3M | — |
| FY2025 | −$192.3M | — |
| FY2024 | −$185.5M | — |
| FY2023 | −$128.1M | — |
| FY2022 | −$82.2M | — |
| FY2021 | −$61.4M | — |
| FY2020 | −$60.6M | — |
| FY2019 | −$25.4M | — |
| FY2018 | −$16.0M | — |
| FY2017 | −$7.1M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$47.7M | — |
| Jun 2026 | −$75.7M | — |
| Mar 2026 | −$56.2M | — |
| Dec 2025 | −$66.0M | — |
| 35 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $177.2M |
| ZYME Zymeworks Inc. compare | −$112.0M |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$112.2M |
| VIR Vir Biotechnology, Inc. compare | −$141.0M |
| IMNM Immunome, Inc. compare | −$229.0M |
| REPL Replimune Group, Inc. | −$245.5M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$310.5M |
| VERA Vera Therapeutics, Inc. compare | −$338.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$508.0M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item